X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Natco Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES NATCO PHARMA ALKEM LABORATORIES/
NATCO PHARMA
 
P/E (TTM) x - 24.3 - View Chart
P/BV x 7.4 18.4 40.3% View Chart
Dividend Yield % 0.6 0.6 94.0%  

Financials

 ALKEM LABORATORIES   NATCO PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
NATCO PHARMA
Mar-14
ALKEM LABORATORIES/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,589877 181.2%   
Low Rs1,232424 290.9%   
Sales per share (Unadj.) Rs417.5223.4 186.8%  
Earnings per share (Unadj.) Rs56.331.1 181.2%  
Cash flow per share (Unadj.) Rs64.740.3 160.7%  
Dividends per share (Unadj.) Rs12.705.00 254.0%  
Dividend yield (eoy) %0.90.8 117.1%  
Book value per share (Unadj.) Rs292.9219.5 133.5%  
Shares outstanding (eoy) m119.5733.07 361.6%   
Bonus/Rights/Conversions -PA-  
Price / Sales ratio x3.42.9 116.1%   
Avg P/E ratio x25.120.9 119.7%  
P/CF ratio (eoy) x21.816.1 135.0%  
Price / Book Value ratio x4.83.0 162.5%  
Dividend payout %22.616.1 140.2%   
Avg Mkt Cap Rs m168,65321,504 784.3%   
No. of employees `000NANA-   
Total wages/salary Rs m9,1711,128 813.3%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m49,9157,389 675.5%  
Other income Rs m1,645167 984.5%   
Total revenues Rs m51,5617,556 682.4%   
Gross profit Rs m8,4821,793 473.0%  
Depreciation Rs m1,006304 330.4%   
Interest Rs m671366 183.1%   
Profit before tax Rs m8,4511,290 655.2%   
Minority Interest Rs m-11446 -245.8%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,606309 520.2%   
Profit after tax Rs m6,7311,027 655.2%  
Gross profit margin %17.024.3 70.0%  
Effective tax rate %19.023.9 79.4%   
Net profit margin %13.513.9 97.0%  
BALANCE SHEET DATA
Current assets Rs m27,0623,681 735.1%   
Current liabilities Rs m15,3243,123 490.7%   
Net working cap to sales %23.57.6 311.1%  
Current ratio x1.81.2 149.8%  
Inventory Days Days6789 74.3%  
Debtors Days Days4159 70.3%  
Net fixed assets Rs m12,6107,685 164.1%   
Share capital Rs m239331 72.3%   
"Free" reserves Rs m34,4906,670 517.1%   
Net worth Rs m35,0277,259 482.5%   
Long term debt Rs m1,212955 126.9%   
Total assets Rs m54,38711,957 454.8%  
Interest coverage x13.64.5 300.8%   
Debt to equity ratio x00.1 26.3%  
Sales to assets ratio x0.90.6 148.5%   
Return on assets %13.611.7 116.8%  
Return on equity %19.214.2 135.8%  
Return on capital %24.920.7 119.9%  
Exports to sales %12.939.4 32.9%   
Imports to sales %3.15.7 54.1%   
Exports (fob) Rs m6,4612,908 222.2%   
Imports (cif) Rs m1,540421 365.7%   
Fx inflow Rs m6,5633,445 190.5%   
Fx outflow Rs m3,012703 428.5%   
Net fx Rs m3,5522,743 129.5%   
CASH FLOW
From Operations Rs m7,2591,440 504.0%  
From Investments Rs m1,864-1,089 -171.2%  
From Financial Activity Rs m-9,273-353 2,629.1%  
Net Cashflow Rs m-150-1 10,067.1%  

Share Holding

Indian Promoters % 66.9 52.0 128.6%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 33.1 7.8 422.2%  
FIIs % 0.0 16.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 26.0 -  
Shareholders   68,381 25,395 269.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  ABBOTT INDIA  STRIDES SHASUN LTD  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of PNB Fraud, Rising Troubles at PSBs, and Top Cues in Focus Today(Pre-Open)

Share markets in India closed on a negative note yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 236 points and the NSE Nifty closed down by 74 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 19, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS